PUNE, India, September 6, 2016 /PRNewswire/ --
ReportsnReports.com adds "Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2016" market research report complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Scleroderma (Systemic Sclerosis) targeted therapeutics development and features dormant and discontinued projects.
Complete report on H2 2016 pipeline review of Scleroderma (Systemic Sclerosis) with 50 market data tables and 14 figures, spread across 184 pages is available at http://www.reportsnreports.com/reports/666491-systemic-sclerosis-scleroderma-pipeline-review-h2-2016.html
Systemic Sclerosis (Scleroderma) pipeline therapeutics constitutes close to 47 molecules. Out of which approximately 42 molecules are developed by Companies and remaining by the Universities/Institutes. Companies discussed in this Scleroderma (Systemic Sclerosis) Pipeline Review, H2 2016 report include Allergan Plc, Angion Biomedica Corp., Antitope Limited, Bayer AG, BioLineRx, Ltd., BiOrion Technologies B.V., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Covis Pharmaceuticals, Inc., CSL Limited, Cumberland Pharmaceuticals, Inc., Digna Biotech, S.L., F. Hoffmann-La Roche Ltd., Fibrocell Science, Inc., GenKyoTex S.A., Gilead Sciences, Inc., GlaxoSmithKline Plc, iBio, Inc., Inventiva, Kadmon Corporation, LLC, MedImmune, LLC, miRagen Therapeutics, Inc., PDX Pharmaceuticals LLC, Peptinov SAS, ProMetic Life Sciences Inc., Ribomic Inc., Sanofi, Stemline Therapeutics, Inc., Stratatech Corporation, Vida Therapeutics Inc. and VivaCell Biotechnology Espana S.L. Drug Profiles mentioned in this research report are abatacept, acALY-18, acetylcysteine, ambrisentan, ANG-3070, belimumab, BL-1110, BOT-191, C-1889, C-82, Cell Therapy for Dermatology and Immunology, CM-101, disitertide, factor XIII (human), FCX-013, GKT-831, GSK-2330811, IBIOCFB-03, ifetroban sodium, IVA-337, JBT-101, KD-025, M-10, MEDI-7734, MGN-4220, Monoclonal Antibodies to Inhibit , L-3RA for Autoimmune Disorders, nintedanib, nitroglycerin, Oligonucleotide for Scleroderma, onabotulinumtoxin A, PAT-048, PBI-4050, PDX-002, PPV-06, RBM-006, riociguat, RP-182, SAR-100842, SAR-317461, Small Molecule to Inhibit NFkB for Immunology and Oncology, SRI-35241, Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis, terguride, tocilizumab, VCE-0048, VEDA-1209 and VTI-1000 Series.
Order a copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=666491
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Furthermore, this report also reviews key players involved in Scleroderma (Systemic Sclerosis) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Scleroderma (Systemic Sclerosis)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Scleroderma (Systemic Sclerosis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Another newly published market research report titled on Warts - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Warts, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Warts and special features on late-stage and discontinued projects. Companies discussed in this research are 3M Drug Delivery Systems, Aclaris Therapeutics, Inc., Agilvax, Inc., Aviragen Therapeutics, Inc., Biogenomics Limited, BioMAS Ltd., Cytovation AS, Foamix Pharmaceuticals Ltd., G&E Herbal Biotechnology Co., Ltd., Laboratories Ojer Pharma S.L., LEO Pharma A/S, Nielsen Biosciences, Inc., Novan, Inc., Novartis AG, Promius Pharma, LLC, RXi Pharmaceuticals Corporation, Tamir Biotechnology, Inc., Verrica Pharmaceuticals Inc. and Zydus Cadila Healthcare Limited. Warts Pipeline market research report of 85 pages is available at http://www.reportsnreports.com/reports/666483-warts-pipeline-review-h2-2016.html
Explore more reports on Pharmaceuticals.
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
2nd Floor, Metropole,
Next to Inox Theatre, Bund Garden Road,
Pune - 411001.
+1 888 391 5441
Connect With Us on:
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts